Reaches Agreement with Inveresk Research
NORTRAN PHARMACEUTICALS INC ("NRT-V;NTRDF-L") - Reaches Agreement with Inveresk
Research
Robert Rieder, Chief Executive Officer of Nortran Pharmaceuticals Inc. (the "Company"), announced
that it has reached an agreement with Inveresk Research, a contract research organization based in
Scotland, U.K., to conduct pre-clinical toxicology studies on the Company's compound for the
treatment of intractable cough.
The Company recently received 5 kilograms of the GMP synthesized compound through its agreement
with Abbott Laboratories, and is preparing to commence the final pre-clinical work with Inveresk in
preparation for filing an upcoming IND and conducting phase I clinical trials. These studies are
expected to last for approximately 6 months and will be conducted at Inveresk's facilities in the U.K.
Inveresk Research is a fully Good Laboratory Practices, Good Manufacturing Practices, and Good
Clinical Practices compliant facility with over 30 years of experience serving the pharmaceutical
industry.
Nortran's cough compound is initially aimed at markets for acute, intractable cough, such as is
experienced by individuals who suffer from asthma, chronic obstructive pulmonary disorder, or lung
cancer. Testing to date has indicated that the Company's cough compound eliminates cough very
effectively, and since it has previously undergone safety trials in humans for another indication, the
Company is confident of the drug's safety profile. Phase I clinical trials are anticipated to begin by mid
1999.
Nortran Pharmaceuticals is a drug discovery company focusing on pathology targeted small
molecules. The Company previously announced a partnership with F. Hoffman La-Roche covering part
of its antiarrhythmic development program in the area of a trial fibrillation. Nortran's current drugs in
development target life-threatening arrhythmias of the heart, pain management, sexual dysfunction and
acute cough.
Warning: The company relies on litigation protection for "forward-looking" statements. TEL: (604)
222-5577
Nortran Pharmaceuticals Inc. FAX: (604) 222-6617
James King, Corporate Communications Email: admin@nortran.com Internet: Website:
nortran.com
______________________________________
(c) Corporate Dissemination Services Inc. All rights reserved.
Tel:(604) 689-1101
Fax:(604) 689-1106
RapidFAX (tm) - To get the NEWS as it happens, call (604) 689-3041.
|
